TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06008860

Intervention type: DRUG
Group type: OTHER
Intervention: Experimental: Primary Cohort
Description: Astepro (azelastine) is a second generation antihistamine, as well as an anti-inflammatory and mast cell stabilizer8. It is available as a 0.1% and 0.15% nasal spray by prescription in the USA and over-the-counter in the European Union (EU). Dosing for adults and adolescents 12 years and older is 1 or 2 sprays per nostril twice daily (0.1%) or 2 sprays per nostril once daily (0.15%)9. It is approved by the FDA for treatment of seasonal allergic rhinitis symptoms (rhinorrhea, sneezing, and nasal pruritus) in adults and children 2 years and older, perennial allergic rhinitis in adults and children ages 6 months and older, and the symptoms of vasomotor rhinitis (rhinorrhea, nasal congestion and postnasal drip) in adults and adolescents 12 years and older9.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator: Primary Cohort - Placebo
Description: A Placebo will be provided by Bayer which features similar color and packaging as azelastine.
Study: NCT06650592

Intervention type: OTHER
Intervention: All patients who were candidates for immediate lymphatic reconstruction (ILR)
Description: All patients who were candidates for immediate lymphatic reconstruction (ILR)
Study: NCT05783596

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Humanized glycoengineered type II anti-CD20 monoclonal antibody, via IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Humanized glycoengineered type II anti-CD20 monoclonal antibody, via IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glofitamab
Description: T-cell bispecific humanized monoclonal antibody, via IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glofitamab
Description: T-cell bispecific humanized monoclonal antibody, via IV infusion.
Study: NCT05284890

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-99677
Description: Specified dose on specified days
Study: NCT04661748

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: real time alarm of deviating vital signs
Description: Intervention consists of actively alerting staff personnel if physiologic vital signs, deviates from certain thresholds
Study: NCT05548556

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive subcutaneous (SC) placebo every 4 weeks (Q4W)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7204239
Description: Participants will receive SC RO7204239 Q4W
Study: NCT04770961

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Erector spinae plane catheter with 0.5% Ropivacaine
Description: Ultrasound guided, right sided, ESP catheter inserted at the level of T5. 20 cc injection of 0.5% Ropivacaine is injected at the time of catheter placement. Postoperatively, a programmed intermittent bolus infusion of 0.2% Ropivacaine will be delivered via the ESP catheter.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Erector spinae plane catheter with saline
Description: Ultrasound guided, right sided, ESP catheter inserted at the level of T5. 20 cc injection of saline is injected at the time of catheter placement. Postoperatively, a programmed intermittent bolus infusion of saline will be delivered via the ESP catheter.
Study: NCT06287905

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prazosin Oral Tablet
Description: 1-Dose and administration of prazosin: 30 μg/kg/dose of prazosin will be delivered orally every 6 hours 4 doses, in adults we shouldn't exceed 1 mg per dose. Prazosin will be delivered using a nasogastric tube while securing the patient's airway in the event of vomiting or unconsciousness. Every 30 minutes for the first three hours, every hour for the following six, and then every four hours until improvement, blood pressure, pulse rate, respiration rate, and oxygen saturation will be measured. When pain is the only symptom, prophylaxis shouldn't be given. To avoid the first-dose phenomenon, the patient should remain in a laying position for around 3 hours (even while the case is being examined) (Shoreit et al., 2019).
Study: NCT05346692

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Survey Administration
Description: Complete Survey

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Interview
Description: Complete Interview

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Text Message-Based Navigation Intervention
Description: Complete mindfulness intervention

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interview
Description: Complete interview
Study: NCT06548880

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Structured exercise program
Description: The intervention applied in this research has an online exercise training conducting with a structured exercise program including different types of exercise which are range of motion, stretching and low intensity aerobic exercises. The exercise program continued with sessions each lasting 60 minutes, once a week for 10 weeks.
Study: NCT05388669

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lazertinib
Description: Lazertinib tablets will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lazertinib
Description: Lazertinib tablets will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amivantamab Subcutaneous and Co-Formulated with Recombinant Human Hyaluronidase (SC CF)
Description: Amivantamab injection will be administered subcutaneously by manual injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amivantamab Intravenous
Description: Amivantamab will be administered by IV infusion.
Study: NCT06504394

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab (+) Berahyaluronidase alfa
Description: SC injection
Study: NCT04875429

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Zenith Fenestrated+ Endovascular Graft in combination with the BeGraft Balloon-Expandable FEVAR Bridging Stent Graft System and Unibody2
Description: Endovascular aneurysm repair
Study: NCT06616246

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HealthyLifetime
Description: HealthyLifetimeTM \[HL\] seeks to intervene early in the aging process when individuals have the best chance for longer-term benefits of changing their health behavior, staving off functional decline, and minimizing the onset or exacerbation of chronic conditions.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: HealthyLifetime
Description: HealthyLifetimeTM \[HL\] seeks to intervene early in the aging process when individuals have the best chance for longer-term benefits of changing their health behavior, staving off functional decline, and minimizing the onset or exacerbation of chronic conditions.
Study: NCT06482489

Intervention type: DEVICE
Intervention: Siemens Magnetom Free.Max 0.55T (Siemens Healthineers, Erlangen, Germany).
Description: Performing low-field MRI to evaluate image quality with patients carrying metallic implants and assess the detection of suspicious prostate lesions.

Intervention type: DEVICE
Intervention: Siemens Magnetom Free.Max 0.55T (Siemens Healthineers, Erlangen, Germany).
Description: Performing low-field MRI to evaluate image quality with patients carrying metallic implants and assess the detection of suspicious prostate lesions.

Intervention type: DEVICE
Intervention: Siemens Magnetom Free.Max 0.55T (Siemens Healthineers, Erlangen, Germany).
Description: Performing low-field MRI to evaluate image quality with patients carrying metallic implants and assess the detection of suspicious prostate lesions.
Study: NCT05706077

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: active tDCS
Description: The electrode will measure 5x5 cm and a current of 2mA will be applied for 20 minutes. The current density will be 0.08mA/cm². tDCS will be applied three times a week for 20 minutes over four weeks.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: active tDCS
Description: The electrode will measure 5x5 cm and a current of 2mA will be applied for 20 minutes. The current density will be 0.08mA/cm². tDCS will be applied three times a week for 20 minutes over four weeks.

Intervention type: DEVICE
Group type: OTHER
Intervention: sham tDCS
Description: The electrode will measure 5x5 cm. The sham-type current will show a rising ramp where the initial 30 seconds will be real current with the same parameter as the active group. After this time, the current will be automatically stopped by the device. tDCS will be applied three times a week for 20 minutes over four weeks.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham tDCS
Description: The electrode will measure 5x5 cm. The sham-type current will show a rising ramp where the initial 30 seconds will be real current with the same parameter as the active group. After this time, the current will be automatically stopped by the device. tDCS will be applied three times a week for 20 minutes over four weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: real Physical Therapy
Description: Manual maneuvers and therapeutic exercises will be performed for 30 minutes, three times a week over four weeks.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: real Physical Therapy
Description: Manual maneuvers and therapeutic exercises will be performed for 30 minutes, three times a week over four weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo Physical Therapy
Description: The placebo Physical Therapy will be applied for 30 minutes, three times a week over four weeks. The initial 20 minutes will be used for the application of simulated ultrasound bilaterally in the middle portion of the upper trapezius muscle. In the final 10 minutes, the researcher will place the palms of the hand under the occipital region without applying any force or movement with the participant in the supine position.

Intervention type: OTHER
Group type: OTHER
Intervention: placebo Physical Therapy
Description: The placebo Physical Therapy will be applied for 30 minutes, three times a week over four weeks. The initial 20 minutes will be used for the application of simulated ultrasound bilaterally in the middle portion of the upper trapezius muscle. In the final 10 minutes, the researcher will place the palms of the hand under the occipital region without applying any force or movement with the participant in the supine position.
Study: NCT05629884

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: COPERIA-REHAB
Description: After the randomization of the patient there will be some preliminary sessions where the means of self-monitoring training and the Borg 1/10 effort scale will be explained and training videos will be shown. Doubts will also be answered.~Afterwards, training will start through the COPERIA-REHAB platform, which will last 8 weeks (6 days per week).
Study: NCT05270005

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound-based flow imaging
Description: Ultrasound-based flow imaging of the carotid artery stenosis will be acquired at baseline and two annual follow-up appointments.

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound-based strain imaging
Description: Ultrasound-based strain imaging of the carotid artery stenosis will be acquired at baseline and two annual follow-up appointments.

Intervention type: DIAGNOSTIC_TEST
Intervention: Conventional duplex
Description: Conventional duplex measurements of the carotid artery stenosis will be acquired at baseline and two annual follow-up appointments.
Study: NCT05381766

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CSA Model
Description: Community-supported agriculture (CSA) involves a community of individuals who support a farm and in return receive distributions of the farm's produce throughout the growing season. Culturally appropriate produce will be provided weekly for 20 weeks to community members in Sunset Park and surrounding neighborhoods. Brooklyn Grange in Sunset Park will grow and provide Chinese specific produce for a fee ranging from $7 to $31 depending on the participant's self-identified situation and Angel Family Farm will grow and provide Mexican specific produce for a fee of up to $15. Participants that receive SNAP benefits can use their EBT card to cover their produce box fees. Education will be offered in the form of nutrition education, cooking tutorials, and farming information provided by staff at Brooklyn Grange.
Study: NCT05916664

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Kinto Care Coaching
Description: Describe the basics of the intervention
Study: NCT05137925

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Cognitive Therapy (MBCT)
Description: MBCT is an 8-week group-based treatment modality designed specifically to prevent recurrence of depressive symptoms. MBCT combines principles of cognitive behavioral therapy and mindfulness meditation to help participants change the way in which they relate to automatic negative thinking patterns that trigger symptom recurrence. Through awareness and acceptance of negative thoughts and emotions, participants learn how to dismiss negative thoughts and to tolerate distress and uncertainty.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual (TAU)
Description: TAU (the control group) provides participants with information about the benefits of mindfulness in pregnancy and offers referrals for psychotherapy in the community. Participants in TAU are contacted monthly via phone or videoconference call to maintain engagement.
Study: NCT05706337

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Propofol 1-2mg / kg was for anesthesia induction. Propofol is a hypnotic agent that is used as an induction agent and as a maintenance anaesthetic delivered by continuous i.v. infusion or intermittent i.v. bolus.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciprofol
Description: Ciprofol 0.2～0.5mg/kg was for anesthesia induction. Ciprofol is an intravenous sedative-hypnotic and a short-acting GABAA receptor agonist. It activates GABAergic neurons by enhancing chloride ion influx. It is used for anesthetic induction and maintenance agents include rapid induction of general anesthesia, rapid return of consciousness, minimal residual effects on the central nervous system and less injection pain.
Study: NCT05978479

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Teach-Back Method
Description: No intervention will be given to the patients in the control group.
Study: NCT04759248

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab + Trastuzumab + Vinorelbine
Description: * Atezolizumab IV 1200 mg in combination with~* Trastuzumab sc 600mg or IV 6mg/kg every 3 weeks and~* Vinorelbine 25 mg/m² IV or 60 mg/m2 PO on days 1 and 8, every 3 weeks during the first cycle and if there are no toxicity signs dose will be increased to 80 mg/m2 PO o 30 mg/m2 IV.
Study: NCT05405725

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ENZ215
Description: Enrolled women with postmenopausal osteoporosis will receive ENZ215 (60mg)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prolia
Description: Enrolled women with postmenopausal osteoporosis will receive Prolia
Study: NCT05907616

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Produce purchase incentive
Description: Participants will be provided with a specific incentive amount per month for 10 months to purchase produce, nutrition education sessions and will be sent text message reminders to redeem their incentives every month and to provide them with nutrition tips.
Study: NCT04732195

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pilocarpine microneedle patch
Description: Each microneedle (MN) patch contains an array of solid, water-soluble, micron-scale needles that encapsulate the medication (Pilocarpine). The patch form can be placed directly on the skin.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pilocarpine Iontophoresis
Description: Pilocarpine Iontophoresis is a process of transdermal pilocarpine delivery by use of a voltage gradient on the skin. An agar gel disc containing pilocarpine is placed under the electrodes which are connected to the Macroduct 3700 Sweat Inducer device.
Study: NCT05266430

Intervention type: OTHER
Intervention: Standard of Care
Description: Patients who are planned to receive plaque radiotherapy for the treatment of IL/CM based on the expert judgment of the investigator

Intervention type: DRUG
Intervention: AU-011
Description: Previously received
Study: NCT05741437

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-378, QD, PO Drug: D745, D150, QD, PO
Description: Durg: CKD-378, QD, PO Drug: D745, D150, QD, PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-378, QD, PO Drug: D745, D150, QD, PO
Description: Durg: CKD-378, QD, PO Drug: D745, D150, QD, PO
Study: NCT06680661

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide (Cy) is one part of the conditioning regimen. 50 mg/kg beginning on day -6.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine (Flu) is one part of the conditioning regimen. 150 mg/m2 (30 mg/m2 per day on days -6 to -2)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiotepa
Description: Thiotepa (Thio) is one part of the conditioning regimen.10 mg/kg (5 mg/kg per day on days -5 and -4)

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total Body Irradiation
Description: 400 cGy (200 cGy per day on days -2 and -1).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Double Umbilical Cord Transplant
Description: Cord blood is a regulated biologic. Selection of cord blood units will be based on published guidelines.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Tacrolimus will be administered post transplant. Graft-versus-host disease prophylaxis will consist of tacrolimus and mycophenolate mofetil (MMF), starting on day-5. Tacrolimus will continue at least until day 180 and then be tapered off.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: MMF will be administered post transplant. Graft-versus-host disease prophylaxis will consist of tacrolimus and mycophenolate mofetil (MMF), starting on day-5. MMF will continue until day 30.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abatacept
Description: Abatacept at a dose of 10mg/kg will be given on days T-1, T+5, T+14 and T+28.
Study: NCT05471817

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elinzanetant (BAY3427080)
Description: Capsule, oral, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate
Description: Capsule, oral, single dose
Study: NCT05233163

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Description: Empagliflozin 10 mg oral daily for 12 weeks
Study: NCT06625515

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATX-559
Description: DHX9 tablets will be taken orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATX-559
Description: DHX9 tablets will be taken orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATX-559
Description: DHX9 tablets will be taken orally
Study: NCT06760481

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiragolumab
Description: Given by IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiragolumab
Description: Given by IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiragolumab
Description: Given by IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Given by IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Given by IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Given by IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Given by IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Given by IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Given by IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Given by IV
Study: NCT06761066

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: NVP-NK4146
Description: BID for 36 weeks orally

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: NVP-NK4146 Placebo
Description: BID for 36 weeks orally
Study: NCT06774079

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirzepatide
Description: Patients in this arm will receive tirzepatide starting at 2.5 mg subcutaneous (SC) weekly for 4 weeks, then increase to 5 mg SC weekly for 4 weeks and then 7.5 mg SC weekly for the last 4 weeks of the intervention period. Place of injection includes abdomen, thigh, or upper arm.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mediterranean diet
Description: The diet is comprised of a content of 25-30 grams of fiber per day (from fruits, vegetables, whole grains) that is low in animal protein and minimally processing of foods The diet arm will receive dietary guidance from our dietician on weekly 30-minute guided sessions. Participants will be encouraged to adhere to the diet for up to three meals per day for the duration of the study.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mediterranean diet
Description: The diet is comprised of a content of 25-30 grams of fiber per day (from fruits, vegetables, whole grains) that is low in animal protein and minimally processing of foods The diet arm will receive dietary guidance from our dietician on weekly 30-minute guided sessions. Participants will be encouraged to adhere to the diet for up to three meals per day for the duration of the study.
Study: NCT06774183

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Near vision glasses for presbyopia correction
Description: Provision of near vision glasses for presbyopia correction to individuals who did not previously have glasses and have correctable presbyopia
Study: NCT06773247

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: I. Myofascial Release Technique ,Cupping Technique and II. Conventional Physical Therapy
Description: The cupping procedure was performed as follows: Massage oil was applied over the area first to improve contact and makes it easier to move the cup's position. double-walled glass cups (6 glasses with diameters from 75 to 100 mm) were held inverted, after which each glass was placed on an afflicted area overlying the low back muscle (acupoint: BL23).~Myofascial Release Technique Vertical stroking technique was performed in lumbar region to quadratus lumborum. AIt was performed as follow; Quadratus lumborum is palpated in prone and side lying for trigger points. The technique is applied by the patient positioned in side lying with a pillow under waist to exaggerate stretch of the muscle. The therapist stands at level of patient's hip posterior and counter pre